[Effects of 3-methyl-4-oxo-2-phenyl-N-[2-piperidinyl) ethyl]-4H-1-benzopyran-8-carboxyamide hydrochloride monohydrate (FL-155), a new anti-pollakiuria agent, on rhythmic bladder contractions in anesthetized rats].
The effects of FL-155, which was synthesized to develop a new orally-active anti-pollakiuria agent, on the rhythmic bladder contractions were studied in anesthetized rats. At a pressure exceeding 10 cm H2O in the bladder, a rhythmic bladder contraction was observed up to at least 120 min. This response was abolished by a spinal (C1 level) cut, cuts of both pelvic nerves, thiopental (3.0 mg/kg, i.v.) or lidocaine (1.0 mg/kg, i.v.); and atropine (0.01 mg/kg, i.v.) strongly inhibited the amplitude of the response. FL-155 and flavoxate, in intravenous (0.3-3.0 mg/kg and 1.0-3.0 mg/kg, respectively) and intraduodenal (12.5-100 mg/kg and 200-400 mg/kg, respectively) administrations, dose-dependently abolished the rhythmic bladder contractions, and FL-155 was 8-16 times more potent than flavoxate in intraduodenal administrations. These results suggest that the rhythmic bladder contraction in anesthetized rat may be a polysynaptic reflex through pelvic nerves and the central nervous system (supraspinal level), and FL-155 appears to be a candidate for an orally active anti-pollakiuria agent.
D000818:Animals; D001285:Atropine / Q000494:pharmacology; D005422:Flavoxate / Q000494:pharmacology; D008012:Lidocaine / Q000494:pharmacology; D008297:Male; D010507:Periodicity; D010880:Piperidines / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D012018:Reflex / Q000187:drug effects*; D013874:Thiopental / Q000494:pharmacology; D001743:Urinary Bladder / Q000187:drug effects* / Q000294:innervation; D014555:Urination Disorders / Q000188:drug therapy*
D010880:Piperidines; D005422:Flavoxate; D001285:Atropine; C051464:FL 155; D008012:Lidocaine; D013874:Thiopental